Literature DB >> 14656359

Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma.

C E Brightling1, F A Symon, S T Holgate, A J Wardlaw, I D Pavord, P Bradding.   

Abstract

BACKGROUND: Airway smooth muscle infiltration by mast cells is a feature of asthma and not eosinophilic bronchitis. In asthma, Th2 cytokines have been implicated as playing a critical role in the development of airway inflammation and hyper-responsiveness. Whether inflammatory cells within the airway smooth muscle release these cytokines is unknown.
METHODS: We have undertaken a comparative immunohistochemical study in bronchial biopsies from 14 subjects with asthma, 10 with eosinophilic bronchitis and eight normal controls recruited from two centres.
RESULTS: The median number of IL-4+ cells/mm2 smooth muscle was significantly higher in subjects with asthma than eosinophilic bronchitis and normal controls for both the anti-IL-4 mAb 3H4 (2.4, 0, 0, respectively; P=0.001) and anti-IL-4 mAb 4D9 (1.6, 0, 0, respectively; P=0.02). There were no group differences in the number of IL-5+ cells (P=0.31). In six subjects with asthma, IL-13 expression by cells within the airway smooth muscle was studied. The median (range) of IL-13+cells was 2 (0.9-2.7). Ninety-four percent of the cells expressing IL-4 (3H4), 92% of those expressing IL-4 (4D9) and 100% expressing IL-13 in the airway smooth muscle were mast cells. Fifty-five percent of the mast cells within the airway smooth muscle co-localized to IL-4 (3H4), 29% to IL-4 (4D9) and 17% to IL-13.
CONCLUSIONS: In asthma, IL-4+ and IL-13+ cells were present within the airway smooth muscle and were expressed predominantly by mast cells, suggesting that IL-4 and IL-13 may play an important role in mast cell-airway smooth muscle interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656359     DOI: 10.1111/j.1365-2222.2003.01827.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  42 in total

1.  Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma.

Authors:  Ryan H Dougherty; Sukhvinder S Sidhu; Kavita Raman; Margaret Solon; Owen D Solberg; George H Caughey; Prescott G Woodruff; John V Fahy
Journal:  J Allergy Clin Immunol       Date:  2010-05       Impact factor: 10.793

Review 2.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

3.  An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Authors:  Chad K Oh; Raffaella Faggioni; Feng Jin; Lorin K Roskos; Bing Wang; Claire Birrell; Rosamund Wilson; Nestor A Molfino
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

4.  Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation.

Authors:  Cong Jin; Christopher P Shelburne; Guojie Li; Erin N Potts; Kristina J Riebe; Gregory D Sempowski; W Michael Foster; Soman N Abraham
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

5.  Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1.

Authors:  Lucy Woodman; Salman Siddiqui; Glenn Cruse; Amanda Sutcliffe; Ruth Saunders; Davinder Kaur; Peter Bradding; Christopher Brightling
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 6.  Cytokine and anti-cytokine therapy in asthma: ready for the clinic?

Authors:  D Desai; C Brightling
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells.

Authors:  William Walker; Gareth D Healey; Julian M Hopkin
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

8.  Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model.

Authors:  S Yamagata; K Tomita; R Sato; A Niwa; H Higashino; Y Tohda
Journal:  Clin Exp Immunol       Date:  2008-09-23       Impact factor: 4.330

9.  A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma.

Authors:  Dave Singh; Binita Kane; Nestor A Molfino; Raffaella Faggioni; Lorin Roskos; Ashley Woodcock
Journal:  BMC Pulm Med       Date:  2010-01-08       Impact factor: 3.317

10.  IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis.

Authors:  Salman Siddiqui; Glenn Cruse; Susan McKenna; William Monteiro; Vijay Mistry; Andrew Wardlaw; Christopher Brightling
Journal:  BMC Pulm Med       Date:  2009-07-14       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.